NCT01592422

Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer

Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: People's Hospital of Guangxi Zhuang Autonomous Region · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The role of maintenance therapy in the management of Small Cell Lung Cancer (SCLC) has not been confirmed. Many treatment modalities like chemotherapy, interferons and other biological agents have been tested as maintenance therapy in SCLC, but the results are disappointing. A marginal survival advantage is seen in maintenance with chemotherapy and interferon-alpha, however, the functioning status and immune system may get worse, which subsequently has a negative impact on patient's quality-of-life. Immunotherapy with autologous cytokine-induced killer (CIK) cells can activate the antitumor defense mechanism through stimulating immune response and altering the interaction between tumor and its host. This effect may result in improved tumor control and survival, as well as a better quality of life. To test the hypothesis, a randomized controlled study was conducted to compare CIK cells with best supportive care as maintenance therapy for SCLC.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Autologous cytokine-induced killer cell	Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
OTHER	Best Supportive Care	Best Supportive Care in the absence of disease progression

Timeline

• Start date: 2012-07-01
• Primary completion: 2015-07-01
• Completion: 2015-09-01
• First posted: 2012-05-07
• Last updated: 2012-07-03

Locations

1 site across 1 country: China